Workshop

W26.2- Improvement in abdominal symptoms (CFAbd-Score) and gut inflammation over 12 months of treatment with Elexacaftor/Tezacaftor/Ivacaftor in children with CF aged 6-11– results from the RECOVER study

Speaker(s)

• 

  Jane C. Davies, MD MBChB MRCP FMedSci (she/her/hers)

  National Heart and Lung Institute, Imperial College London